Nanjing Geneleap Biotech

Geneleap Biotech is a biotechnology company headquartered in Nanjing, China, specializing in the research and development of RNA-based therapeutics and vaccines. The company leverages its proprietary lipid nanoparticle (LNP) delivery system and mRNA synthesis platform to address significant unmet needs in infectious diseases, oncology, and metabolic disorders. Geneleap's pipeline includes mRNA-based vaccines for viral infections and siRNA candidates for chronic diseases, currently in preclinical stages. Founded by a team of international experts, the company aims to optimize the delivery and expression of RNA molecules to improve clinical outcomes. Geneleap is actively expanding its technological capabilities through strategic collaborations and internal innovation in the field of precision medicine.